Skip to main content

Viloxazine (Qelbree): A Faster Strattera?

On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/

 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

The Link Between Autism and Trauma

The millions of Americans with autism and other developmental issues are more vulnerable to emotional trauma, often from bullying or sexual abuse. What can you do if this has happened to someone in your life?

ADHD Algorithm

Parents and caregivers need to understand medications and therapies available to help manage ADHD. In this podcast, Mara and I will explore options for ADHD and the process of selecting more effective treatments.
Teens on the couch

Motivational Interviewing for Teens: Focus on Marijuana

Lots of teens use marijuana and many of these kids suffer significant harm from it. But just telling teens to stop is unlikely to work. This case based webinar will help you learn how to help teens reduce their use and the problems it brings.